Abstracts tagged "Adverse events"

Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon², Lianne Kearsley-Fleet³, Ian N. Bruce^4,5, Hector Chinoy^6,7, Anne Barton^6,8, Mark Lunt⁹, Kath Watson³, Deborah P.M. Symmons¹, Kimme L. Hyrich³ and on behalf of the BSRBR-RA, ¹Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁸NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting
Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial
Maarten Boers^1,2, Sarah Leatherman³, James R. O'Dell⁴ and Jeffrey R. Curtis⁵, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ³MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Birmingham VAMC, Birmingham, AL
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…
Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Gerd Burmester¹, Gurjit S. Kaeley², Arthur Kavanaugh³, Cem Gabay⁴, Daryl MacCarter⁵, Peter Nash⁶, Tsutomu Takeuchi⁷, Anabela Cardoso⁸, Shufang Liu⁹, Hartmut Kupper¹⁰ and Jasmina Kalabic¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of Florida, Jacksonville, FL, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁶Department of Medicine, University of Queensland, Brisbane, Australia, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Torre Oriente, AbbVie, Lisboa, Portugal, ⁹Immunology Development, AbbVie, North Chicago, IL, ¹⁰AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…
Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting
Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Jeffrey R. Curtis¹, Marc de Longueville², Cathy O'Brien² and Boulos Haraoui³, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Brussels, Belgium, ³Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
Abstract Number: 573 • 2015 ACR/ARHP Annual Meeting
Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Jennie Best¹, Amanda Farr², Gregory Lenhart², Khaled Sarsour¹, Marni Stott-Miller² and Yong Gil Hwang³, ¹Genentech, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Oral glucocorticoids are commonly used to treat rheumatoid arthritis (RA). However, their use may be associated with potential adverse events. Therefore, the objective was…
Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Arunima Agarwal¹, Anusha Ramanathan² and Rhina Castillo³, ¹Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…
Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
René Cordtz¹, Lene Mellemkjær², Bente Glintborg¹, Merete Lund Hetland³ and Lene Dreyer¹, ¹Department of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ³DANBIO Registry and Department of Rheumatology., Copenhagen University Hospital Glostrup. On behalf of all departments of Rheumatology in Denmark., Glostrup, Denmark
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…
Abstract Number: 503 • 2014 ACR/ARHP Annual Meeting
Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial
Varun Dhir¹, Amit Sandhu¹, Jasbinder Kaur², Nidhi Gupta¹, Prabhdeep Kaur¹, Ankita Sood¹, Aman Sharma³ and Shefali Sharma¹, ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Government Medical College and hospital Sector 32, Chandigarh, India, ³Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose There is good evidence that folic acid 5-10mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this data…
Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Bei-Hung Chang^1,2, Lien Quach¹, Mary Brophy³, Keri Hannagan⁴, Edward C. Keystone⁵, Ted R. Mikuls⁶ and James R. O'Dell⁷, ¹VA Boston Healthcare System, Boston, MA, ²Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ³VA Boston Heathcare System, Boston, MA, ⁴MAVERIC, VA Boston Heathcare System, Boston, MA, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…
Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].